Literature DB >> 18753719

[A patient with early Alzheimer's disease who showed improvement of cognitive function and cerebral perfusion by combined therapy of nilvadipine and PPAR gamma agonists].

Tomohiko Sato1, Haruo Hanyu, Tomotaka Akai, Akira Takasaki, Hirofumi Sakurai, Toshihiko Iwamoto.   

Abstract

A 76-year-old man was referred to our hospital because of memory impairment. He was diagnosed as having early Alzheimer's disease, in addition to hypertension and type II diabetes mellitus. Nilvadipine (a Ca-channel blocker), telmisartan (an angiotension II receptor blocker), and pioglitazone (an insulin sensitizer) were administered for the control of the hypertension and diabetes. After 6 months of treatment, the scores on verbal fluency (animals and vegetables/60 seconds) and frontal assessment battery of the patient improved despite no significant changes on the Mini-Mental State Examination and Alzheimer's Disease Assessment Scale. Moreover, follow-up examination of SPECT demonstrated an improvement of cerebral perfusion in the frontal and temporoparietal regions. In addition to nilvadipine, a highly lipophilic Ca channel antagonist agent that easily penetrates the central nervous system, PPARgamma agonists, such as pioglitazone and termisartan, may have had favourable effects on cognitive function and cerebral perfusion in this patient.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753719     DOI: 10.3143/geriatrics.45.428

Source DB:  PubMed          Journal:  Nihon Ronen Igakkai Zasshi        ISSN: 0300-9173


  4 in total

Review 1.  Roles of AMP-activated protein kinase in Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Keshen Li; Sohel H Quazi; Bin Zhao
Journal:  Neuromolecular Med       Date:  2012-02-26       Impact factor: 3.843

2.  Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier.

Authors:  Daniel Paris; Corbin Bachmeier; Nikunj Patel; Amita Quadros; Claude-Henry Volmar; Vincent Laporte; Jim Ganey; David Beaulieu-Abdelahad; Ghania Ait-Ghezala; Fiona Crawford; Michael J Mullan
Journal:  Mol Med       Date:  2010-12-17       Impact factor: 6.354

3.  YY-1224, a terpene trilactone-strengthened Ginkgo biloba, attenuates neurodegenerative changes induced by β-amyloid (1-42) or double transgenic overexpression of APP and PS1 via inhibition of cyclooxygenase-2.

Authors:  Zheng-Yi Li; Yoon Hee Chung; Eun-Joo Shin; Duy-Khanh Dang; Ji Hoon Jeong; Sung Kwon Ko; Seung-Yeol Nah; Tae Gon Baik; Jin Hyeong Jhoo; Wei-Yi Ong; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  J Neuroinflammation       Date:  2017-04-27       Impact factor: 8.322

4.  A Network-Based Approach to Explore the Mechanisms of Uncaria Alkaloids in Treating Hypertension and Alleviating Alzheimer's Disease.

Authors:  Wenyong Wu; Zijia Zhang; Feifei Li; Yanping Deng; Min Lei; Huali Long; Jinjun Hou; Wanying Wu
Journal:  Int J Mol Sci       Date:  2020-03-04       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.